Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Moxifloxacin for Complicated Skin and Skin Structure Infections
NCT00402727Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2006
- Primary completion
- Jun 2008
- Modality
- Orthosteric Ligands
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of moxifloxacin in Skin and Skin Structure Infection (SSSI) (2 arms), sponsored by Bayer. Primary endpoint: Percentage of Cured Participants as Determined by the Data Review Committee (DRC). Started Sep 2006; status: completed.
02
Drugs
moxifloxacin
03
Conditions
Skin and Skin Structure Infection (SSSI)
Beyond the preview
Go deeper on NCT00402727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00402727.